Reposted by Tero JärvinenFICEBO @ficebo.bsky.social · 02/10/2026What do patients really want to know about recovery? Read more about the idea, our collaboration with Aalto University students, and the next steps: www.ficebo.com/post/how-can... Photo source: Aalto University 011
Reposted by Tero JärvinenTimothy Caulfield @caulfieldtim.bsky.social · 13/09/2026NO evidence this kinda DATA DATA DATA tech helps health outcomes. Wellness & longevity marketing push idea that more data is always better and empowering. Not true. How Oura’s rings found their way onto millions of fingers www.economist.com/business/202...economist.comHow Oura’s rings found their way onto millions of fingersIts business is booming as consumers look to take charge of their health 85713
Reposted by Tero JärvinenFICEBO @ficebo.bsky.social · 13/09/2026Meet Leo, research intern at FICEBO! This summer, upper secondary school student Leo worked on developing an online course on evidence-based medicine. #FICEBO #EvidenceBasedMedicine #ResearchInternship 011
Reposted by Tero JärvinenMolecular Therapy Family of Journals @moltherapy.bsky.social · 10/09/2026The latest issue of Molecular Therapy Advances features original research focused on a dual-AAV otoferlin gene therapy for congenital deafness, anti-CAR antibodies in patients treated with anti-BCMA CAR T cell therapy, and more. bit.ly/4cWWPVl 032
Reposted by Tero Järvinenregenmedlab.bsky.social @regenmedlab.bsky.social · 04/09/2026How do human large blood vessels respond to hypoxia? Paucity of evidence until large arteries & veins collected after severe lower extremity trauma reveal rapid, but transient intimal hyperplasia and adventitial angiogenesis from veins. @evborg.bsky.social @navbo.bsky.social rdcu.be/XyAQYUmiqQma 011
Reposted by Tero Järvinenregenmedlab.bsky.social @regenmedlab.bsky.social · 03/09/2026We are in Halo! Our drug screening technology for homing and tissue penetrating macrocyclic peptides based on in vivo phage display & microdialysis (www.life-science-alliance.org/content/8/5/...) & macrocyclic homing peptides for targeted drug delivery are presented. www.halo.science/profile/tero...halo.scienceTero Järvinen's profileTero Järvinen is a Principal Investigator at Tampere University. Expertise in Biopharmaceutics, Cardiovascular, Molecular Biology. Explore collaboration opportunities on Halo Science. 011
Reposted by Tero JärvinenMRC-LMB Cell Biology Division @cellbiol-mrclmb.bsky.social · 28/08/2026Great tribute to the discovery by Barbara Pearce of clathrin, the first protein found to act in membrane traffic, along with her mentoring and support of the pioneers (many of whom were other women) who revealed the workings of this key player in cellular function. 03419
Reposted by Tero JärvinenTraffic @traffic-journal.bsky.social · 28/08/2026Happy 50th anniversary, Clathrin! onlinelibrary.wiley.com/doi/full/10.... @effc.bsky.social 03621
Reposted by Tero JärvinenFICEBO @ficebo.bsky.social · 27/08/2026FICEBO’s Thomas Ibounig co-authored a new JAMA Internal Medicine review with researchers Romi Haas and Rachelle Buchbinder from Monash University. Read more about the study and Thomas’s upcoming dissertation on our website: www.ficebo.com/post/new-rev... 011
Tero Järvinen @terojarvinen.bsky.social · 16/08/2026"Fragile skin may benefit from decoration" commentary on @nystromlab.bsky.social publication on the potential of decorin-based therapeutics for the treatment of RDEB. @matrixbiologie.bsky.social @epidermophyte.bsky.social @charitydebra.bsky.social Take a look www.sciencedirect.com/science/arti...sciencedirect.comFragile skin may benefit from decorationAll content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply. 030
Tero Järvinen @terojarvinen.bsky.social · 16/08/2026Together w. Dr. Y. Liao we wrote a commentary on @nystromlab.bsky.social publication on the potential of decorin-based therapeutics for the treatment of RDEB. Take a look at "Fragile skin may benefit from decoration" @matrixbiologie.bsky.social www.sciencedirect.com/science/arti... 010
Tero Järvinen @terojarvinen.bsky.social · 15/08/2026Fragile skin may benefit from decoration: Molecular Therapy Advances www.cell.com/molecular-th...cell.comFragile skin may benefit from decorationRecessive dystrophic epidermolysis bullosa (RDEB) is a severe hereditary blistering disorder characterized by fragility of the skin and mucous membranes due to mutations in the COL7A1 gene, which enco... 020
Reposted by Tero JärvinenJames Ball @jamesrball.com · 15/07/2026Honestly, the way the entire pub chants "wanker" any time Infantino appears on screen is truly heartwarming. 151156139
Tero Järvinen @terojarvinen.bsky.social · 18/06/2026Hot off the press! We demonstrate in Cancer Res that the αv integrin- and neuropilin-1 (NRP-1)-dual targeting iRGD peptide (in phase II clinical trials) reverses some of these tumor microenvironment features by inhibiting TGF-β activation in the tumor: aacrjournals.org/cancerres/ar... 011
Reposted by Tero Järvinenpipsasaharinen.bsky.social @pipsasaharinen.bsky.social · 15/06/2026Glad to see @jci.org featuring our study on endothelial RTK/integrin crosstalk—where ANGPT2 simultaneously engages two receptors! Big thanks to @johannaivaska@bsky.social and all co-authors and funders. @HelsinkiUniMed @helsinkiuni doi.org/10.1172/JCI1... #vascularbiologydoi.org JCI - Inactive β1-integrin acts as a junctional scaffold for angiopoietin/TIE2/FOXO1 signaling 063
Tero Järvinen @terojarvinen.bsky.social · 15/05/2026Hot off the press! We demonstrate in @theaacr.bsky.social that the αv integrin- and neuropilin-1 (NRP-1)-dual targeting iRGD peptide (in phase II clinical trials) reverses some of these tumor microenvironment features by inhibiting TGF-β activation in the tumor aacrjournals.org/cancerres/ar... 041
Reposted by Tero JärvinenFICEBO @ficebo.bsky.social · 13/05/2026Congratulations to Tappara on the win once again! 🏆 We’re proud to see one of our researchers Raine Sihvonen celebrating with the team as Tappara’s doctor. Our researchers do many things, and supporting sports is one of them! #Tappara #Research #IceHockey #Orthopedics 122
Reposted by Tero JärvinenMartin González-Rodriguez @immuno-martin.bsky.social · 08/05/2026With some big delays, but it's nice to see the fruitful collaboration with @terojarvinen.bsky.social and @carolinacabalin.bsky.social out in a nice package! 262
Reposted by Tero JärvinenFICEBO @ficebo.bsky.social · 07/05/2026MedicalResearch.com now interview with Teppo Järvinen, Professor of Orthopaedics and Traumatology, University of Helsinki and HUS. You can find more information about the interview here: medicalresearch.com/nejm-arthros...medicalresearch.comNEJM: Arthroscopic Partial Meniscectomy Provided No Benefit Over Placebo Surgery and May Worsen Longterm OutcomesThis study contributes to the concept of medical reversal, where widely used treatments are shown to be ineffective or harmful when tested rigorously. 022
Reposted by Tero JärvinenNEJM.org @nejm.org · 03/05/2026In the FIDELITY trial of arthroscopic partial meniscectomy for degenerative medial meniscal tear in adults, participant-reported and radiologic outcomes over 10 years of follow-up suggested no benefit and possible harm from the procedure. Full trial results: nej.md/48Pkwww #Orthopedics 1144
Reposted by Tero JärvinenNEJM.org @nejm.org · 07/05/2026Three must-read articles that sparked major news coverage in April. 053
Reposted by Tero JärvinenGareth Moore @garethmoore.bsky.social · 30/04/2026Over the moon to see this work from my PhD finally published in Development! Using a combination of structural biology and genetics we identify an avidity-driven mechanism of BMP signal control in the extracellular space. (1/11) 33510
Tero Järvinen @terojarvinen.bsky.social · 30/04/2026In 2002, I watched hundreds of surgeons jump out of their seats to blast a speaker. @nejm.org Arthroscopic Partial Meniscectomy for Degenerative Tear — 10-Year Outcomes | New England Journal of Medicine www.nejm.org/doi/full/10....nejm.orgArthroscopic Partial Meniscectomy for Degenerative Tear — 10-Year Outcomes | NEJMIn this trial of arthroscopic partial meniscectomy for degenerative medial meniscal tear in adults, participant-reported and radiologic outcomes over 10 years of follow-up suggested no benefit and ... 111
Tero Järvinen @terojarvinen.bsky.social · 30/04/2026Hot off the press! ☝️ Arthroscopic Partial Meniscectomy for Degenerative Tear — 10-Year Outcomes | New England Journal of Medicine www.nejm.org/doi/full/10....nejm.orgArthroscopic Partial Meniscectomy for Degenerative Tear — 10-Year Outcomes | NEJMIn this trial of arthroscopic partial meniscectomy for degenerative medial meniscal tear in adults, participant-reported and radiologic outcomes over 10 years of follow-up suggested no benefit and ... 000
Reposted by Tero JärvinenFICEBO @ficebo.bsky.social · 29/04/2026www.nejm.org/doi/full/10....nejm.orgArthroscopic Partial Meniscectomy for Degenerative Tear — 10-Year Outcomes | NEJMIn this trial of arthroscopic partial meniscectomy for degenerative medial meniscal tear in adults, participant-reported and radiologic outcomes over 10 years of follow-up suggested no benefit and ... 022
Reposted by Tero JärvinenFICEBO @ficebo.bsky.social · 29/04/2026The FIDELITY 10-year results have been published in the New England Journal of Medicine. You can find the full article through the link in the comments. #FIDELITY #NEJM #MedicalResearch 121
Reposted by Tero JärvinenPirjo Toivonen @pirjot.bsky.social · 29/04/2026A significant milestone for the field and a proud moment for everyone involved. ✨ 011
Tero Järvinen @terojarvinen.bsky.social · 27/04/2026Dr. Tuomas Komulainen, M.D. wrapped up his PhD Thesis demonstrating that the recruitment of anti-inflammatory M2 macrophages are important for keloid resolution after corticosteroids therapy. A double-blinded, randomized, controlled trial. @thejidjournal.bsky.social www.jidonline.org/article/S002...jidonline.orgAnti-Inflammatory Macrophages Are Recruited to the Keloids that Obtain Response to Intralesional Injection Therapies: Before and After Treatment Biopsies from a Double-Blinded, Randomized, Controlled ...We explored the predictive value of immune cell populations to intralesional injections using biopsies collected from the active border of keloids before and after injections in the double-blinded ran... 010
Reposted by Tero JärvinenPirjo Toivonen @pirjot.bsky.social · 24/04/2026Have you heard about this? #TBT #ThrowBackThursday #EBM #placebo #RCT #FIDELITYtrial 011
Reposted by Tero JärvinenFICEBO @ficebo.bsky.social · 23/04/2026www.nejm.org/doi/10.1056/...nejm.orgArthroscopic Partial Meniscectomy versus Sham Surgery for a Degenerative Meniscal Tear | NEJMArthroscopic partial meniscectomy is one of the most common orthopedic procedures, yet rigorous evidence of its efficacy is lacking. We conducted a multicenter, randomized, double-blind, sham-contr... 021
Reposted by Tero JärvinenFICEBO @ficebo.bsky.social · 23/04/2026#TBT to one of our most widely recognized publications: the 1-year results of FIDELITY. Find the publication link in the comments. 121
Reposted by Tero JärvinenDEBRA UK @charitydebra.bsky.social · 16/04/2026Since our research programme began, we have invested an average of £500,000 a year in pioneering EB research - £24 million so far. This sustained commitment is accelerating treatment breakthroughs, improving quality of life & bringing us closer to a world where EB no longer limits lives. 🦋 011
Reposted by Tero JärvinenFICEBO @ficebo.bsky.social · 15/04/2026www.ficebo.com/post/ficebo-...ficebo.comFICEBO at Hemsedal 2026 011
Reposted by Tero JärvinenFICEBO @ficebo.bsky.social · 12/04/2026Welcoming a new junior researcher Venla-Linnea Karjalainen to the team. Venla-Linnea is a medical student at Tampere University and alongside her medical studies, she works on research in hand surgery and orthopaedics in FICEBO. 011
Tero Järvinen @terojarvinen.bsky.social · 10/04/2026www.tuni.fi/en/news/tero... Honored to receive this recognition from Tampere Univ.🏆 This award belongs to the incredible team behind the work: Marianne Karlsberg, Toini Pemmari, Soili Lehtonen, and Ulrike May. Thanks to collaborators at @unitartupress.bsky.social (Teesalu Lab) and NYMC (Liao Lab).tuni.fi 010
Tero Järvinen @terojarvinen.bsky.social · 10/04/2026www.tuni.fi/fi/ajankohta...tuni.fiTero Järvinen on Tampereen yliopiston Vuoden keksijä | Tampereen korkeakouluyhteisöEpidermolysis bullosa on vakava harvinainen ihosairaus, joka vaikeissa tautimuodoissa johtaa kuolemaan jo vauvana ja lievemmissäkin muodoissa aggressiivisiin ihosyöpiin. Tampereen yliopiston Vuoden... 020
Reposted by Tero JärvinenFICEBO @ficebo.bsky.social · 06/04/2026In conversation with Jarkko Jokihaara. Interview by Alan Cassels. Read more on our website: www.ficebo.com/post/meet-dr... 011
Reposted by Tero JärvinenPirjo Toivonen @pirjot.bsky.social · 06/04/2026Interview is particularly interesting, as Jarkko Jokihaara reflects on the history of trapeziectomy — and once again this reminds us why it is important to study the effectiveness of procedures already used in clinical practice. 011
Tero Järvinen @terojarvinen.bsky.social · 31/03/2026Our work is out @eurjimmunol.bsky.social Dynamic Thymic Stromal Lymphopoietin and Its Receptor Complex Expression on Skin Langerhans Cells in Skin Inflammation - González‐Rodríguez - 2026 - European Journal of Immunology - Wiley Online Library onlinelibrary.wiley.com/doi/10.1002/...onlinelibrary.wiley.comDynamic Thymic Stromal Lymphopoietin and Its Receptor Complex Expression on Skin Langerhans Cells in Response to MC903‐induced Skin InflammationThymic Stromal Lymphopoietin (TSLP) regulates the skin microenvironment during type 2 inflammation. Epidermal APCs, Langerhans cells (LCs), might be the target of TSLP, but whether LCs express CD127 ... 053
Reposted by Tero JärvinenTimothy Caulfield @caulfieldtim.bsky.social · 30/03/2026So much grift in stem cell space. Seeing more influencers leverage “regenerative” rhetoric. We been studying stem cell hype and unproven therapies for almost 20 yrs! And it just gets worse and worse. tbh, the phrase “stem cells” now a big red flag for BUNK! 🚩 🚩 🚩 🚩 🚩 🚩 5514
Reposted by Tero JärvinenPirjo Toivonen @pirjot.bsky.social · 30/03/2026Great to be part of the team!✨ 011
Reposted by Tero JärvinenTimothy Caulfield @caulfieldtim.bsky.social · 03/03/2026In this testing & data obsessed time, studies like this good reminder often useless & harmful! Over 40? Your rotator cuff probably looks a little rough www.sciencenews.org/article/shou... Study: "RC abnormalities nearly universal after age 40 years & routine imaging should NOT guide diagnosis..."sciencenews.orgOver 40? Your rotator cuff probably looks a little roughMRI scans of over 600 Finnish adults found that nearly all had frayed, torn or otherwise abnormal rotator cuffs — yet most had no symptoms. 12112
Reposted by Tero JärvinenFICEBO @ficebo.bsky.social · 06/03/2026“Almost as Common as Grey Hair” Recent study from our group finds that after midlife, rotator cuff changes on MRI are almost as expected as grey hair. Now the lead author Thomas Ibounig explains the recent FIMAGE study findings in depth: www.ficebo.com/post/almost-...ficebo.com“Almost as Common as Grey Hair”: New FICEBO study finds that after midlife, rotator cuff changes on MRI are almost as expected as grey hair 011
Reposted by Tero JärvinenFICEBO @ficebo.bsky.social · 11/03/2026You may have noticed a shift in our social media posts lately. That’s because Hongfei has joined our team to help share our research with a wider audience! Read more about Hongfei on our website: www.ficebo.com/people/hongf... 022
Reposted by Tero JärvinenFICEBO @ficebo.bsky.social · 24/03/2026Milloin valita olkamurtuman hoidoksi ortoosi ja milloin leikkaus? Tutkijamme arvioivat eri hoitomuotojen kustannusvaikuttavuutta FISH-tutkimuksessa, heidän kommenttinsa tuloksista voit lukea HUS uutisesta. ➡️ Verkkosivulla myös linkki alkuperäiseen tutkimusartikkeliin www.hus.fi/ajankohtaist...hus.fiLeikkaushoito on kustannustehokas vaihtoehto olkavarren murtumissaTutkimus osoittaa, että olkavarren murtuman leikkaushoito on yhteiskunnalle ortoosia edullisempi vaihtoehto. Lue, miten asiaa tutkittiin. 011
Reposted by Tero JärvinenFICEBO @ficebo.bsky.social · 26/03/2026We welcome our newest researcher to the team, Dr Amir Sobhani, bringing fresh perspectives and expertise to drive our work forward. Check out his full bio on our website: www.ficebo.com/people/amir-... 021
Tero Järvinen @terojarvinen.bsky.social · 12/03/2026Shouldering uncertainty open.substack.com/pub/unrelent...open.substack.comShouldering uncertainty(03/09/2026) Week 196 000
Reposted by Tero JärvinenJAMA Internal Medicine @jamainternalmed.com · 16/02/2026#RotatorCuff abnormalities on #MRI were found in 99% of adults aged 41–76, including 96% of asymptomatic shoulders, indicating most findings are age-related rather than disease. ja.ma/4aiQPVU 111
Tero Järvinen @terojarvinen.bsky.social · 16/02/2026Incidental Rotator Cuff Abnormalities on Magnetic Resonance Imaging url: jamanetwork.com/journals/jam... 020